Four Products: Predicting Diffusion Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

Product A (Industrial Component): 12% CAGR over 5 years; 22% gross margin.
Product B (Consumer Appliance): 8% CAGR; 34% gross margin; high customer acquisition cost.
Product C (Software Subscription): 45% ARR growth; 85% retention rate.
Product D (Medical Device): Flat growth; 60% gross margin; high regulatory barrier.

Operational Facts

Product A relies on direct B2B sales force.
Product B requires retail distribution partnerships.
Product C requires continuous R&D investment for updates.
Product D requires clinical trial validation before scale.

Stakeholder Positions

VP Sales: Prioritizes Product A for volume and existing relationships.
CMO: Advocates for Product B brand equity.
CTO: Pushes Product C as the future of the firm.
Regulatory Lead: Cautions against premature scaling of Product D.

Information Gaps

Market penetration data for Product D is missing.
Customer churn cost for Product B is not quantified.
Competitor pricing data for Product A is absent.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

Which product warrants the primary allocation of limited capital and management focus to maximize long-term firm valuation?

Structural Analysis

Diffusion Dynamics: Product C follows a network effect model; Product D follows a high-barrier adoption curve.
Resource Allocation: The firm cannot sustain four distinct go-to-market motions simultaneously without diluting execution.

Strategic Options

Option 1: The Focused SaaS Pivot. Divest Products A and B. Concentrate all capital on Product C. Trade-off: High immediate revenue loss; high long-term margin upside.
Option 2: The B2B Core Strategy. Scale Product A and D. Sunset B and C. Trade-off: Stable cash flows; limited growth potential.
Option 3: Balanced Portfolio. Maintain status quo with incremental funding. Trade-off: Guaranteed mediocrity; lack of competitive dominance in any segment.

Preliminary Recommendation

Pursue Option 1. Product C is the only asset with the unit economics and scalability to redefine the firm's valuation floor. The other products are legacy distractions.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

Month 1-3: Initiate formal divestiture process for Products A and B.
Month 4-6: Reallocate engineering headcount from A/B/D to C.
Month 7-12: Execute aggressive customer acquisition for Product C.

Key Constraints

Talent Retention: Current engineers are specialized in hardware; Product C requires software expertise.
Sales Transition: Moving from transactional hardware sales to recurring subscription sales requires a complete overhaul of the incentive structure.

Risk-Adjusted Implementation

Retain a skeleton crew for Product D to maintain regulatory compliance while seeking a strategic buyer. This mitigates the risk of total loss on the medical device investment while freeing up the balance sheet.

4. Executive Review and BLUF (Executive Critic)

BLUF

The firm is currently managing four distinct businesses, none of which receive sufficient capital to dominate. The recommendation to focus on Product C is correct. However, the plan underestimates the difficulty of transitioning a hardware-centric culture to a software-subscription model. Divestiture of A and B must be handled as a priority to avoid cash burn during the transition. If the firm cannot recruit a software-native leadership team by month four, the pivot will fail. The strategy is approved, provided the divestiture is treated as the primary operational objective, not a secondary task.

Dangerous Assumption

The assumption that the current engineering team can be retrained for Product C is flawed. Software and hardware development require different mental models and organizational structures.

Unaddressed Risks

Cultural Friction: The existing sales force will resist the shift to subscription models, leading to a high attrition rate of top performers. (Probability: High; Consequence: Critical).
Market Timing: Competitors may launch a rival to Product C while the firm is distracted by the divestiture of A and B. (Probability: Medium; Consequence: High).

Unconsidered Alternative

Spin off Product C into a separate entity. This would allow the firm to attract venture capital specifically for the software unit while keeping the stable cash flows of the hardware business, rather than burning them during the transition.